Filing Flows › Myriad Genetics (MYGN) › Q3 2026
Myriad Genetics (MYGN) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
Myriad Genetics (MYGN) reported revenue of $203M for the third quarter 2026 (Q3 2026), -1% from a year earlier and +6% from the quarter before. Operating margin was -19.7%, net loss $43.9M (21.7% of revenue).
Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%, net loss $43.9M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $203M | +6% | -1% |
| Operating profit | −$39.9M | — | — |
| Net earnings | −$43.9M | — | — |
| Operating cash flow | −$6.5M | — | -131% |
What changed
Revenue was $202.7M in Q3 2026, down 1% year over year and up 6% from the previous quarter. Cancer Care Continuum was the largest line at 61% of revenue. Prenatal Health lost $5.2M year over year (down 12%), 173% of the total change.
Gross margin was 67.9%, down 2.0 points from Q3 2025. Operating costs exceeded revenue by $39.9M, an operating margin of -19.7%. Operating expenses grew 6% against a revenue fall of 1%. The fastest-growing cost line was Sales & marketing (+18%). The quarter ended with a net loss of $43.9M, wider than the previous quarter's $43.2M loss.
Operating cash flow was −$6.5M. Non-cash charges added back $12.6M of depreciation and amortization and $9.2M of share-based compensation. Working capital and other items added $15.6M. Capital expenditures of $1.8M exceeded it, leaving free cash flow of −$8.3M.
Questions
What was Myriad Genetics' revenue in the third quarter 2026?
Myriad Genetics (MYGN) reported revenue of $203M for the third quarter 2026 (Q3 2026), -1% from a year earlier and +6% from the quarter before.
Was Myriad Genetics profitable in the third quarter 2026?
Operating loss was $39.9M (-19.7% of revenue) and net loss $43.9M.
Source: Myriad Genetics 10-Q on SEC EDGAR.